protegerin but not receptor activator of NF-Kappa B ligand correlates withLarsen score in rheumatoid asthritis. Ann Rheum Dis 2004; 63: 216-7.56. Romas E, Gillespie Mt, Martin TJ. Involvement of receptor activator of NF-Kappa B ligand and tumor necrosis factor-<strong>al</strong>pha in bone destruction inrheumatoid asrthritis. Bone 2002; 30: 340-6.57. Norschen AR, Kaser A, Enrich B, Ludwiczek O, Gabriel M, Obrist P, WolfAM. The RANKL /OPG system is activated in inflammatory bowel diseaseand relates to the state of bone loss. Gut 2005; 54: 479-87.58. Ulivieri FM, Piodi LP, Taioli E, Lisciandrano D, Ranzi T, Vezzoli M, et <strong>al</strong>. Boneminer<strong>al</strong> density and body composition in ulcerative colitis: a six-year follow-up.Osteoporos Int 2001;12:343-8.59. Siffledeen JS, Fedorak RN, Siminoski K, Jen H, Vaudan E, Abraham N, et<strong>al</strong>. Bones and Crohn’s: risk factors associated with low bone miner<strong>al</strong> densityin patients with Crohn’s disease. Inflamm Bowel Dis 2004; 10: 220-228.60. Habtezion A, Silverberg MS, Parkes R, Mikolainis S, Steinhart AH. Risk factorsfor low bone density in Crohn’s disease. Inflamm Bowel Dis 2002; 8:87-92.61. Schulte C, Dignass AU, Mann K, Goebell H. Bone loss in patients with inflammatorybowel disease is less than expected: a follow-up study. ScandJ Gastroenterol 1999; 34: 696-702.62. Jahnsen J, F<strong>al</strong>ch JA, Mowinckel P, Aadland E. Bone miner<strong>al</strong> density in patientswith inflammatory bowel disease: a population-based prospectivetwo-year follow-up study. Scand J Gastroenterol 2004; 39: 145-53.63. Bernstein CN, Seeger M, Sayre JW , Anton PA, Artinian L, Shanahan F. Decreasedbone density in inflammatory disease is related to corticoesteroiduse and not disease diagnosis. J Bone Miner Res 1995; 10: 250-6.64. Van Staa TP, Leufkens HGM, Abenhaim L, Zhang B, Cooper C . Use of or<strong>al</strong>corticosteroids and risk of fractures. J Bone Miner Res 2000; 15: 993-1000.65. Boot AM, Bouquet J, Krenning EP, de Muinck Keizer-Schrama SMPF. Boneminer<strong>al</strong> density and nutrition<strong>al</strong> status in children with chronic inflammatorybowel disease. Am J Gastroenterol 1998; 93: 1483-90.66. Gokh<strong>al</strong>e R, Favus MJ, Karrison T, Sutton MM, Rich B, Kirschner BS. Boneminer<strong>al</strong> density assesment in children with inflammatory bowel disease.Gastroenterology 1998; 114: 902-11.67. McCarthy D, Duggan P, O´Brien M, Kiely M, McCarthy J, Shanahan F, et<strong>al</strong>. Season<strong>al</strong>ity of vitamin D status and bone turnover in patients withCrohn´s disease. Aliment Pharmacol Ther 2005; 21: 1073-83.68. Vogelsang H, Ferenci P, Woloszczuk W. Bone disease in vitamin D-deficientpatients with Crohn´s disease. Gastroenterology 1982; 83: 1252-8.69. Silvennoinen J, Risteli L, Kattunen T, Risteli J. Increased degradation oftype I collagen in patients with inflammatory bowel disease. Gut 1996;38: 223-8.70. Odell, WD. Testosterone treatment of men treated with glucocorticoids(editori<strong>al</strong>). Arch Intern Med 1996; 156: 1133.71. D´Haens G, Verstraete K, Cheyns K et <strong>al</strong>. Bone turnover during short-termtherapy with metilprednisolone or budesonide in Crohn´s disease. AlimentPharmacolo Ther. 1998: 12: 410-24.72. Silvennoinen JA, Lethola JK, Niemela SE. Smoking is a risk factor for osteoporosisin women with inflammatory bowel disease. Scand J. Gastroenterol1996; 31: 367-71.73. Robinson RJ, Krzywicki T, Almond L<strong>al</strong>-Azzawi F, Abrams K, Iqb<strong>al</strong> SJ, MayberryJF. Effect of a low-impact exercise program on bone miner<strong>al</strong> densityin Crohn´s disease: a randomized controlled tri<strong>al</strong>. Gastroenterology 1988;115: 36-41.74. Thomas G.A. Rhodes J. Green J.T. Inflammatory Bowel Disease and Smoking—AReview. 1998; 93: 144-9 .75. Shea B, Wells G, Cranney A, Zytaruk N, Robinson V, Griffith L, et <strong>al</strong>. WITH-DRAWN: C<strong>al</strong>cium supplementation on bone loss in postmenopaus<strong>al</strong> women.Cochrane Database Syst Rev 2007: CD004526.76. Papadimitropoulos E, Wells G, Shea B, Gillespie W, Weaver B, Zytaruk N,et <strong>al</strong>. Meta-an<strong>al</strong>yses of therapies for postmenopaus<strong>al</strong> osteoporosis. VIII:Meta-an<strong>al</strong>ysis of the efficacy of vitamin D treatment in preventing osteoporosisin postmenopaus<strong>al</strong> women. Endocr Rev 2002; 23: 560-9.77. Gillespie WJ, Avenell A, Henry DA, O’Connell DL, Robertson J. Vitamin Dand vitamin D an<strong>al</strong>ogues for preventing fractures associated with involution<strong>al</strong>and post-menopaus<strong>al</strong> osteoporosis. Cochrane Database Syst Rev2001: CD000227.78. Jackson RD, LaCroix AZ, Gass M, W<strong>al</strong>lace RB, Robbins J, Lewis CE et <strong>al</strong>.C<strong>al</strong>cium plus vitamin D supplementation and the risk of fractures. N EnglJ Med 2006; 354: 669-83.79. Bernstein CN, Seeger LL, Anton PA, Artinian L, Geffrey S, Goodman W et<strong>al</strong>. A randomized, placebo- controlled tri<strong>al</strong> of c<strong>al</strong>cium supplementationfor decreased bone density in corticosteroid-using patients with inflammatorybowel disease: a pilot study. Aliment Pharmacol Ther 1996; 10:777-86.80. Boonen S, Rizzoli R, Meunier PJ, Stone M, Nuki G, Syversen U et <strong>al</strong>. Theneed for clinic<strong>al</strong> guidance in the use of c<strong>al</strong>cium and vitamin D in the managementof osteoporosis: a consensus report. Osteoporos Int 2004; 15:511-9.81. Menchén L, Ripoll C, Bretón I Moreno M, De la Cuerda C ,Camblor M. et<strong>al</strong>. Osteoporosis y enfermedad inflamatoria intestin<strong>al</strong>. Nutr Hosp 2005;20: 26-37.82. Chesnut CH 3rd, Silverman S, Andriano K, Genant H, Gimona A, HarrisS, et <strong>al</strong>. A randomized tri<strong>al</strong> of nas<strong>al</strong> spray s<strong>al</strong>mon c<strong>al</strong>citonin in postmenopaus<strong>al</strong>of osteoporotic fractures study. PROOF Study Group. Am J Med2000; 109: 267-276.83. Cranney A, Wells G, Willan A, Griffith L, Zytaruk N, Robinson V et <strong>al</strong>.Metaan<strong>al</strong>ysesof therapies for postmenopaus<strong>al</strong> osteoporosis. II. Meta-an<strong>al</strong>ysisof <strong>al</strong>endronate for the treatment of postmenopaus<strong>al</strong> women. Endocr Rev2002; 23: 508-16.84. Cranney A, Tugwell P, Adachi J, Weaver B, Zytaruk N, Papaioannou A, et<strong>al</strong>. Meta-an<strong>al</strong>yses of therapies for postmenopaus<strong>al</strong> osteoporosis. III. Metaan<strong>al</strong>ysisof risedronate for the treatment of postmenopaus<strong>al</strong> osteoporosis.Endocr Rev 2002; 23: 517-23.85. Rosen CJ, Hochberg MC, Bonnick SL, McClung M, Miller P, Broy S, et<strong>al</strong>.Treatment with once-weekly <strong>al</strong>endronate 70 mg compared with onceweekly risedronate 35 mg in women with postmenopaus<strong>al</strong> osteoporosis:a randomized double-blind study. J Bone Miner Res 2005; 20: 141-51.86. Hosking D, Adami S, Felsenberg D, Andia JC, V<strong>al</strong>imaki M, Benhamou L,et <strong>al</strong>. Comparison of change in bone resorption and bone miner<strong>al</strong> densitywithonce-weekly <strong>al</strong>endronate and daily risedronate: a randomised,placebo-controlled study. Curr Med Res Opin 2003; 19: 383-94.87. Bonnick S, Saag KG, Kiel DP, McClung M, Hochberg M, Burnett SM, et<strong>al</strong>. Comparison of weekly treatment of postmenopaus<strong>al</strong> osteoporosis with<strong>al</strong>endronate versus risedronate over two years. J Clin Endocrinol Metab2006; 91: 2631-7.88. Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, et <strong>al</strong>.Alendronate for the prevention and treatment of glucocorticoid-inducedosteoporosis. Glucocorticoid-Induced Osteoporosis Intervention StudyGroup. N Engl J Med 1998; 339: 292-9.89. Adachi JD, Saag KG, Delmas PD, Liberman UA, Emkey RD, Seeman E, et<strong>al</strong>. Two-year effects of <strong>al</strong>endronate on bone miner<strong>al</strong> density and vertebr<strong>al</strong>fracture in patients receiving glucocorticoids: a randomized, double-blind,placebo-controlled extension tri<strong>al</strong>. Arthritis Rheum 2001; 44: 202-11.194 • Enfermedad Inflamatoria Intestin<strong>al</strong> <strong>al</strong> día - Vol. 7 - Nº. 2 - 2008
Enfermedades asociadas90. W<strong>al</strong>lach S, Cohen S, Reid DM, Hughes RA, Hosking DJ, Laan RF et <strong>al</strong>.Effects of risedronate treatment on bone density and vertebr<strong>al</strong> fracturein patients on corticosteroid therapy. C<strong>al</strong>cif Tissue Int 2000; 67:277-85.91. Cohen S, Levy RM, Keller M, Boling E, Emkey RD, Greenw<strong>al</strong>d M, et <strong>al</strong>. Risedronatetherapy prevents corticosteroid-induced bone loss: a twelvemonth,multicenter, randomized, double-blind, placebo-controlled, par<strong>al</strong>lel-groupstudy. Arthritis Rheum 1999; 42: 2309-18.92. Cranney A, Welch V, Adachi JD, Guyatt G, Krolicki N, Griffith L, et <strong>al</strong>. Etidronatefor treating and preventing postmenopaus<strong>al</strong> osteoporosis. CochraneDatabase Syst Rev 2001: CD003376.93. Adachi JD, Roux C, Pitt PI, Cooper C, Moniz C, Dequeker J, et <strong>al</strong>. A pooleddata an<strong>al</strong>ysis on the use of intermittent cyclic<strong>al</strong> etidronate therapy forthe prevention and treatment of corticosteroid induced bone loss. J Rheumatol2000; 27:2424-31.94. Delmas PD, Adami S, Strug<strong>al</strong>a C, Stakkestad JA, Reginster JY, FelsenbergD, et <strong>al</strong>. Intravenous ibandronate injections in postmenopaus<strong>al</strong> womenwith osteoporosis: one-year results from the dosing intravenous administrationstudy. Arthritis Rheum 2006; 54: 1838-4695. Ringe JD, Dorst A, Faber H, Ibach K, Sorenson F. Intermittent intravenousibandronate injections reduce vertebr<strong>al</strong> fracture risk in corticosteroid-inducedosteoporosis: results froma long-term comparative study. OsteoporosInt 2003; 14: 801-7.96. Haderslev, KV. Tjellesen L, Sorensen HA, Staun M. Alendronate increaseslumbar spine bone miner<strong>al</strong> density in patients with Crohn's disease. Gastroenterology2000; 119: 639-46.97. Henderson S, Hoffman N, Prince R. A double-blind placebo-controlled studyof the effects of the bisphosphonate risedronate on bone mass in patientswith inflammatory bowel disease. Am J Gastroenterol 2006; 101: 119-23.98. Bartram SA, Peaston RT, Rawlings DJ, Francis RM, Thompson NP. A randomizedcontrolled tri<strong>al</strong> of c<strong>al</strong>cium with vitamin D, <strong>al</strong>one or in combinationwith intravenous pamidronate, for the treatment of low bone miner<strong>al</strong>density associated with Crohn’s disease. Aliment Pharmacol Ther 2003;18: 1121-7.99. Stokkers PC, Deley M, Van Der Spek M, Verberne HJ, Van Deventer SJ,Hommes DW. Intravenous pamidronate in combination with c<strong>al</strong>cium andvitamin D: highly effective in the treatment of low bone miner<strong>al</strong> densityin inflammatory bowel disease. Scand J Gastroenterol 2006; 41: 200-20.100.Seeman E, Crans GG, Diez-Perez A, Pinette KV, Delmas PD. Anti-vertebr<strong>al</strong>fracture efficacy of r<strong>al</strong>oxifene: a meta-an<strong>al</strong>ysis. Osteoporos Int 2006; 17:313-6.101.Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, et<strong>al</strong>. Effect of parathyroid hormone (1-34) on fractures and bone miner<strong>al</strong>density in postmenopaus<strong>al</strong> women with osteoporosis. N Engl J Med 2001;344: 1434-41.102.Orwoll ES, Scheele WH, Paul S, Adami S, Syversen U, Diez-Perez A, et <strong>al</strong>.Theeffect of teriparatide [human parathyroid hormone (1-34)] therapy on bonedensity in men with osteoporosis. J Bone Miner Res 2003; 18: 9-17.103.Hodsman AB, Bauer DC, Dempster DW, Dian L, Hanley DA, Harris ST, Kendleret <strong>al</strong>. Parathyroid hormone and teriparatide for the treatment of osteoporosis:a review of the evidence and suggested guidelines for its use.Endocr Rev 2005; 26: 688-703.195 • Enfermedad Inflamatoria Intestin<strong>al</strong> <strong>al</strong> día - Vol. 7 - Nº. 2 - 2008
Change language